US2006031950A1PendingUtilityA1

Non-mammalian transgenic animal model for cellular proliferative diseases

54
Assignee: FOGARTY PATRICKPriority: Aug 4, 1999Filed: Jun 30, 2005Published: Feb 9, 2006
Est. expiryAug 4, 2019(expired)· nominal 20-yr term from priority
Inventors:Patrick Fogarty
A01K 67/68C12N 15/8509A01K 2267/0331A01K 67/0271C07K 14/82A01K 2217/05A01K 2227/706
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Non-mammalian, transgenic animals, e.g. flies, that exhibit neoplastic phenotypes, i.e. spontaneously produce metastatic tumors, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, and particularly neoplastic, diseases. Finally, kits for screening compounds for anti-neoplastic activity are provided.

Claims

exact text as granted — not AI-modified
1 . A non-mammalian transgenic animal, wherein said transgenic animal spontaneously develops metastatic tumors and comprises a v-myb transgene.  
   
   
       2 . The transgenic non-mammalian animal according to  claim 1 , wherein said transgenic non-mammalian animal is an invertebrate.  
   
   
       3 . The transgenic non-mammalian animal according to  claim 2 , wherein said invertebrate is an insect.  
   
   
       4 . A transgenic fly that spontaneously develops metastatic tumors and comprises a v-myb transgene.  
   
   
       5 . The transgenic fly according to  claim 4 , wherein said fly is a member of the family Drosophilidae.  
   
   
       6 . The transgenic fly according to  claim 5 , wherein said fly is a  Drosophila melanogaster.    
   
   
       7 . The transgenic fly according to  claim 4 , wherein said v-myb transgene is expressed in the amnioserosa and peripheral nervous system.  
   
   
       8 . A transgenic  Drosophila melanogaster  that spontaneously develops metastatic tumors and comprises a v-myb transgene.  
   
   
       9 . A method of screening a compound for activity with respect to cellular proliferative diseases, said method comprising: 
 administering said compound to a non-mammalian animal according to  claim 1;  and    observing the effect of said compound on said animal.    
   
   
       10 . The method according to  claim 9 , wherein said non-mammalian animal is a transgenic invertebrate.  
   
   
       11 . The method according to  claim 10 , wherein said invertebrate is an insect.  
   
   
       12 . The method according to  claim 11 , wherein said insect is a fly.  
   
   
       13 . The method according to  claim 9 , wherein said compound is orally administered to said animal.  
   
   
       14 . A method of screening a compound for activity with respect to a neoplastic disease, said method comprising: 
 feeding said compound to a non-mammalian animal according to  claim 1;  and    observing the effect of said compound on said animal.    
   
   
       15 . The method according to  claim 14 , wherein said compound is present in a nutrient medium.  
   
   
       16 . A method of screening a plurality of compounds for activity with respect to cellular proliferative disease, said method comprising: 
 feeding said plurality of compounds to a plurality of non-mammalian animals according to  claim 1  in a manner sufficient to ensure that each animal is fed only a single type compound from said plurality of compounds; and    observing the effect of said compounds on said plurality of animals.    
   
   
       17 . The method according to  claim 16 , wherein said compound is present in a nutrient medium. (nutrient medium includes water)  
   
   
       18 . A method of identifying whether a gene is capable of modulating a neoplastic disease condition, said method comprising: 
 mutating said gene in a non-mammalian animal according to  claim 1;  and    determining whether said mutation modulates the phenotype of said non-mammalian animal model.    
   
   
       19 . The method according to  claim 18 , wherein said modulating is enhancing.  
   
   
       20 . The method according to  claim 18 , wherein said modulating is suppressing.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.